Vizgen Raises $48M to Propel Push in Spatial Biology and Multiomics Tools

Ryan Cross
ENDPOINTS NEWS
Senior Science Correspondent

Vizgen, a startup that has developed techniques to map how genes and proteins are expressed across different cells, has raised a $48 million Series E financing to ramp up production and sales of its tools.

It’s been a tumultuous couple of years for Vizgen and the broader spatial biology field that its instruments empower. Vizgen and several other companies, each with its own cutting-edge techniques, have been tied up in a spiderweb of legal disputes over who owns the technologies.

But after settling its litigation with instrument maker 10X Genomics and Harvard University last year, Vizgen is ready to scale up manufacturing of its instruments and reagents and get them into the hands of more scientists.

“All parties are now off to the races,” Vizgen CEO Rob Carson told Endpoints News. “There is not a one-size-fits-all technology. One spatial biology solution is not the same as the other.”